

CLINICAL PERFORMANCE OF FOUR FECAL CALPROTECTIN ASSAYS FROM SMARTPHONE-BASED HOME TEST TO HIGH THROUGHPUT CENTRAL LAB METHODS

Thomas Schuster

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

A comparative study of 128 stool samples found that four BÜHLMANN fecal calprotectin assay platforms (ELISA, PETIA, lateral flow, and smartphone-based home test) showed comparable performance for differentiating IBS from IBD, with no significant differences in ROC curve analysis.

KEY POINTS

- ROC analysis showed area under the curve values ranging from 0.827 to 0.835 for IBS versus IBD differentiation, with no significant difference between the four assay methods tested
- At BÜHLMANN cut-offs for IBS/IBD differentiation, all methods achieved 90.8 percent sensitivity at 80 micrograms per gram and 67.3 to 71.2 percent specificity at 160 micrograms per gram
- At IBD monitoring cut-offs, sensitivity at 100 micrograms per gram ranged from 85.5 to 88.2 percent and specificity at 300 micrograms per gram ranged from 82.7 to 86.5 percent across methods
- The study authors conclude that the methods can be used interchangeably depending on patient and care team needs, though all authors are employees of BÜHLMANN Laboratories AG

VIEW THIS CONTENT ON GUTFLIX

<https://gutflifx.eu/search/d/6446b7a2-743c-11ee-9ea7-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.